Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
<p>Abstract</p> <p>Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment fail...
Main Authors: | Giordano Antonio, Miele Lucio, Ciarapica Roberta, Locatelli Franco, Rota Rossella |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-05-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1741-7015/9/63 |
Similar Items
-
Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)
by: Changchien Yi-Che, et al.
Published: (2012-10-01) -
Notch signaling in pediatric soft tissue sarcomas
by: Rota Rossella, et al.
Published: (2012-11-01) -
Novel Natural Inhibitors Targeting Enhancer of Zeste Homolog 2: A Comprehensive Structural Biology Research
by: Weihang Li, et al.
Published: (2021-10-01) -
Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis
by: Sebastian C. B. Bremer, et al.
Published: (2022-06-01) -
Enhancer of zeste homolog 2 regulates cell differentiation and proliferation in neuroblastoma
by: Amallia N. Setyawati, et al.
Published: (2014-12-01)